Gastroretentive Drug Delivery Systems Industry Overview
The global gastroretentive drug delivery systems market size was valued at USD 11.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 6.4% from 2021 to 2028. Pharmaceutical companies are taking initiative with changing requirements and are constantly investing in developing gastroretentive drug delivery systems (DDSs) is the factor estimated to augment market growth. The rising disease burden throughout the world and proven efficacy of gastroretentive drug delivery systems in addressing several gastric-related disorders such as gastric ulcer, and peptic ulcer are anticipated to accelerate the overall market progression.
The market for gastroretentive drug delivery systems experienced a mild impact of the ongoing COVID-19 pandemic in some regions due to production restrictions during mid-2020. However, the restraining effect was negated with growing demand, online prescriptions, and e-pharmacy services. The market in Japan was unimpacted during the first wave of COVID-19 owing to its well-established healthcare infrastructure.
Gather more insights about the market drivers, restraints and growth of the Global Gastroretentive Drug Delivery Systems market
Helicobacter pylori infection is among the most common human infection globally. According to the article published by the University of Arizona, H.pylori infection is higher in developing countries than the developed countries. The incidence of new infections in developing countries is 3 to 10% of the population compared to 0.5% in developed economies. H. Pylori infection is among the known cause of gastroduodenal ulcer disease, gastritis, and gastric cancer. The prevention and management of the disorder can be achieved by enhancing mucosal protection and decreasing the level of gastric acidity. Gastroretentive drug delivery systems extend the gastric retention time, thereby aggregating the concentration of the drug at the application site, possibly reducing essential dosage and improving its bioavailability. The increasing prevalence of H. pylori infection globally is anticipated to boost the growth of the market for gastroretentive drug delivery systems.
Gastroretentive Drug Delivery (GRDD) technology has emerged as an efficient approach for the controlled delivery of various therapeutic molecules which enhances bioavailability. In current years, technological and scientific advancements are made in research and development activities of rate-controlled oral drug delivery methods by overcoming physiological difficulties, including unpredictable gastric emptying times and short gastric residence times. GRDDS has potential application to advance the oral delivery of drugs, for which extended retention in the upper GI tract can enhance their oral bioavailability as well as their therapeutic outcome.
Currently, technological and scientific advancements are undertaken for rate-controlled oral drug delivery systems by disabling physiological difficulties, including unpredictable gastric emptying times as well as short gastric residence times. Thus, to overcome such difficulties, the gastroretentive drug delivery system is designed for longer gastric retention time and will prolong the time within which drug absorption can occur, thereby surging its preference among patients.
Browse through Grand View Research's Healthcare Industry Related Reports
Drug Delivery Devices Market - The global drug delivery devices market size was valued at USD 215.4 billion in 2019 and is anticipated to expand at a CAGR of 6.15% over the forecast period.
Subcutaneous Drug Delivery Devices Market - The global subcutaneous drug delivery devices market size was valued at USD 21.2 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 10.4% from 2020 to 2027.
Gastroretentive Drug Delivery Systems Industry Segmentation
Grand View Research has segmented the global gastroretentive drug delivery systems market on the basis of type, dosage form, distribution channel, and region:
Gastroretentive DDS Type Outlook (Revenue, USD Million, 2016 - 2028)
- High Density Systems
- Expandable Drug Delivery Systems
- Bioadhesive Drug Delivery Systems
- Floating Drug Delivery Systems
- Others
Gastroretentive DDS Dosage Form Outlook (Revenue, USD Million, 2016 - 2028)
- Tablets
- Liquid
- Microspheres
- Capsule
- Others
Gastroretentive DDS Distribution Channel Outlook (Revenue, USD Million, 2016 - 2028)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Gastroretentive Drug Delivery Systems Regional Outlook (Revenue, USD Million, 2016 - 2028)
- North America
- Europe
- Asia Pacific
- Latin America
- MEA (Middle East & Africa)
Key Companies profiled:
Some prominent players in the global Gastroretentive Drug Delivery Systems Industry include
- Hoffmann La Roche
- Ranbaxy
- GlaxoSmithKline
- Pharmacia
- Depomed
- Alcon, Inc.
- Lupin
- Galanix
- Sun Pharma
Order a free sample PDF of the Gastroretentive Drug Delivery Systems Market Intelligence Study, published by Grand View Research.
No comments:
Post a Comment